Cencora, Inc. (NYSE:COR) Given Average Rating of “Moderate Buy” by Analysts

Cencora, Inc. (NYSE:COR) has been assigned an average recommendation of “Moderate Buy” from the twelve research firms that are presently covering the firm, Marketbeat reports. Four investment analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $371.0909.

A number of equities analysts have weighed in on COR shares. Wells Fargo & Company increased their price target on shares of Cencora from $354.00 to $405.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 11th. Mizuho upped their price objective on Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. TD Cowen lifted their target price on Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a report on Monday, November 10th. Wall Street Zen downgraded Cencora from a “buy” rating to a “hold” rating in a research report on Friday, November 28th. Finally, UBS Group raised their price objective on Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a report on Friday, November 7th.

Cencora Stock Up 0.6%

COR opened at $337.43 on Friday. Cencora has a 12 month low of $223.92 and a 12 month high of $377.54. The business has a 50-day moving average of $339.40 and a two-hundred day moving average of $309.16. The company has a debt-to-equity ratio of 4.32, a current ratio of 0.90 and a quick ratio of 0.55. The stock has a market capitalization of $65.42 billion, a price-to-earnings ratio of 42.44, a price-to-earnings-growth ratio of 1.59 and a beta of 0.63.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, topping the consensus estimate of $3.79 by $0.05. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The business had revenue of $83.73 billion for the quarter, compared to analyst estimates of $83.36 billion. During the same period in the prior year, the firm posted $3.34 EPS. The company’s revenue was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, research analysts expect that Cencora will post 15.37 earnings per share for the current year.

Cencora Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 14th were issued a $0.60 dividend. The ex-dividend date was Friday, November 14th. This is a positive change from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 annualized dividend and a yield of 0.7%. Cencora’s payout ratio is 30.19%.

Insider Buying and Selling

In other Cencora news, CEO Robert P. Mauch sold 5,097 shares of the business’s stock in a transaction that occurred on Monday, October 20th. The shares were sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the completion of the sale, the chief executive officer directly owned 37,940 shares in the company, valued at $12,398,792. The trade was a 11.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Chairman Steven H. Collis sold 31,350 shares of the firm’s stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the completion of the transaction, the chairman directly owned 305,913 shares in the company, valued at approximately $88,671,942.18. This represents a 9.30% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 46,640 shares of company stock worth $14,099,338. 10.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Cencora

Several institutional investors and hedge funds have recently modified their holdings of the stock. Atlantic Edge Private Wealth Management LLC raised its holdings in shares of Cencora by 70.0% during the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after buying an additional 35 shares during the period. Costello Asset Management INC acquired a new stake in Cencora in the first quarter valued at approximately $28,000. IAG Wealth Partners LLC purchased a new stake in shares of Cencora during the third quarter valued at approximately $30,000. Vermillion & White Wealth Management Group LLC lifted its position in shares of Cencora by 69.4% during the second quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock worth $31,000 after purchasing an additional 43 shares in the last quarter. Finally, Cloud Capital Management LLC purchased a new position in shares of Cencora in the third quarter valued at $31,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.